Abstract
A clinical decision report appraising:
Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2020;382(13):1219-1231. https://doi.org/10.1056/NEJMoa1910182
for a patient with transfusion-dependent beta-thalassemia.
DOI
10.22237/crp/1622160060
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
FREIJ JB. Luspatercept diminishes the need for red blood cell replacement in transfusion-dependent β-thalassemia patients. Clin. Res. Prac. May 28 2021;7(1):eP2570. https://doi.org/10.22237/crp/1622160060
Included in
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons, Hepatology Commons, Internal Medicine Commons, Pediatrics Commons, Translational Medical Research Commons
